FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2149093312> ?p ?o ?g. }

• W2149093312 endingPage "94" @default.
• W2149093312 startingPage "88" @default.
• W2149093312 abstract "Abstract Background: Mycophenolate mofetil (MMF) is widely used in organ transplantation to prevent acute rejection. Because MMF can produce hematologic and/or gastrointestinal toxicity, therapeutic monitoring is becoming mandatory. This study was designed to investigate the relationship between the clinical events and the pharmacokinetics of mycophenolic acid (MPA) in adult renal transplantation. Methods: Thirty-one adult kidney recipients were prospectively included in the study. MPA pharmacokinetic profiles (blood sampling at 0, 0.5, 1, 2, 4, 6, and 12 h after MMF oral dose) were obtained after transplantation (desired creatinine clearance, 40 mL/min), at 3 months after grafting, and at every clinical event (e.g., side effect or rejection). All patients received a 10-day course of anti-thymocyte globulin, cyclosporine, MMF (1 g twice daily), and steroids. Results: We divided the 31 patients into two groups (groups 1 and 2). Ten patients (32%; group 1) had uneventful outcomes, and 21 patients (68%; group 2) presented with MPA-related side effects. For groups 1 and 2, the MPA trough concentrations (Cmin) were 1.63 ± 1.07 and 2.29 ± 1.16 mg/L, respectively (P = 0.06), and the areas under the curve (AUCs) for MPA from t0 to t12 h (MPA-AUC0–12h) were 39.80 ± 15.29 and 62.10 ± 21.07 mg · h/L, respectively (P = 0.0005, two-sample t-test). Three patients experienced acute graft rejection after the oral MMF dose was reduced because of side effects. In this group, the MPA-Cmin and MPA-AUC were significantly lower by the time acute rejection occurred (1.00 ± 0.45 mg/L and 25.00 ± 6.20 mg · h/L, respectively). At a fixed dose (1 g twice per day), we compared the pharmacokinetic parameters of MPA [Cmin, the MPA concentration 30 min after the oral dose of MMF (C30), and AUC] according to the presence or absence of side effects in the two groups. Cmin and AUC did not differ between the two groups [Cmin = 2.22 ± 1.13 vs 2.17 ± 1.13 mg/L (P = 0.9); AUC = 66.82 ± 29.87 vs 55.70 ± 11.74 mg · h/L (P = 0.11)]; and C30 was significantly higher in group 2 than in group 1 (C30 = 32.99 ± 12.59 vs 7.45 ± 5.40 mg/L; P &lt;0.0001). Conclusions: Our results demonstrate a pharmacokinetic/pharmacodynamic relationship between MPA and clinical events. At a fixed dose of 2 g/day, a high C30 is associated with increased risk for side effects. This study suggests that dividing the MMF daily oral dose into more than two divided doses might prevent early MPA toxicity." @default.
• W2149093312 created "2016-06-24" @default.
• W2149093312 creator A5016994339 @default.
• W2149093312 creator A5031616871 @default.
• W2149093312 creator A5033080476 @default.
• W2149093312 creator A5049204096 @default.
• W2149093312 creator A5059567423 @default.
• W2149093312 creator A5059608367 @default.
• W2149093312 creator A5061797041 @default.
• W2149093312 creator A5080521587 @default.
• W2149093312 date "2001-01-01" @default.
• W2149093312 modified "2023-09-26" @default.
• W2149093312 title "Correlation of Mycophenolic Acid Pharmacokinetic Parameters with Side Effects in Kidney Transplant Patients Treated with Mycophenolate Mofetil" @default.
• W2149093312 cites W1891570058 @default.
• W2149093312 cites W1981535286 @default.
• W2149093312 cites W1993856621 @default.
• W2149093312 cites W2008808603 @default.
• W2149093312 cites W2017733095 @default.
• W2149093312 cites W2025501899 @default.
• W2149093312 cites W2056909500 @default.
• W2149093312 cites W2060752790 @default.
• W2149093312 cites W2081993545 @default.
• W2149093312 cites W2084624308 @default.
• W2149093312 cites W2105427480 @default.
• W2149093312 cites W2172121516 @default.
• W2149093312 cites W2609602266 @default.
• W2149093312 cites W4230996310 @default.
• W2149093312 cites W50336179 @default.
• W2149093312 cites W66541766 @default.
• W2149093312 doi "https://doi.org/10.1093/clinchem/47.1.88" @default.
• W2149093312 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11148182" @default.
• W2149093312 hasPublicationYear "2001" @default.
• W2149093312 type Work @default.
• W2149093312 sameAs 2149093312 @default.
• W2149093312 citedByCount "181" @default.
• W2149093312 countsByYear W21490933122012 @default.
• W2149093312 countsByYear W21490933122013 @default.
• W2149093312 countsByYear W21490933122014 @default.
• W2149093312 countsByYear W21490933122015 @default.
• W2149093312 countsByYear W21490933122016 @default.
• W2149093312 countsByYear W21490933122017 @default.
• W2149093312 countsByYear W21490933122018 @default.
• W2149093312 countsByYear W21490933122019 @default.
• W2149093312 countsByYear W21490933122020 @default.
• W2149093312 countsByYear W21490933122021 @default.
• W2149093312 countsByYear W21490933122022 @default.
• W2149093312 countsByYear W21490933122023 @default.
• W2149093312 crossrefType "journal-article" @default.
• W2149093312 hasAuthorship W2149093312A5016994339 @default.
• W2149093312 hasAuthorship W2149093312A5031616871 @default.
• W2149093312 hasAuthorship W2149093312A5033080476 @default.
• W2149093312 hasAuthorship W2149093312A5049204096 @default.
• W2149093312 hasAuthorship W2149093312A5059567423 @default.
• W2149093312 hasAuthorship W2149093312A5059608367 @default.
• W2149093312 hasAuthorship W2149093312A5061797041 @default.
• W2149093312 hasAuthorship W2149093312A5080521587 @default.
• W2149093312 hasBestOaLocation W21490933121 @default.
• W2149093312 hasConcept C112705442 @default.
• W2149093312 hasConcept C126322002 @default.
• W2149093312 hasConcept C126894567 @default.
• W2149093312 hasConcept C22979827 @default.
• W2149093312 hasConcept C2778033501 @default.
• W2149093312 hasConcept C2778335254 @default.
• W2149093312 hasConcept C2780252810 @default.
• W2149093312 hasConcept C2780272996 @default.
• W2149093312 hasConcept C2780303639 @default.
• W2149093312 hasConcept C2780306776 @default.
• W2149093312 hasConcept C2909675724 @default.
• W2149093312 hasConcept C2909935303 @default.
• W2149093312 hasConcept C2911091166 @default.
• W2149093312 hasConcept C71924100 @default.
• W2149093312 hasConcept C90924648 @default.
• W2149093312 hasConceptScore W2149093312C112705442 @default.
• W2149093312 hasConceptScore W2149093312C126322002 @default.
• W2149093312 hasConceptScore W2149093312C126894567 @default.
• W2149093312 hasConceptScore W2149093312C22979827 @default.
• W2149093312 hasConceptScore W2149093312C2778033501 @default.
• W2149093312 hasConceptScore W2149093312C2778335254 @default.
• W2149093312 hasConceptScore W2149093312C2780252810 @default.
• W2149093312 hasConceptScore W2149093312C2780272996 @default.
• W2149093312 hasConceptScore W2149093312C2780303639 @default.
• W2149093312 hasConceptScore W2149093312C2780306776 @default.
• W2149093312 hasConceptScore W2149093312C2909675724 @default.
• W2149093312 hasConceptScore W2149093312C2909935303 @default.
• W2149093312 hasConceptScore W2149093312C2911091166 @default.
• W2149093312 hasConceptScore W2149093312C71924100 @default.
• W2149093312 hasConceptScore W2149093312C90924648 @default.
• W2149093312 hasIssue "1" @default.
• W2149093312 hasLocation W21490933121 @default.
• W2149093312 hasLocation W21490933122 @default.
• W2149093312 hasOpenAccess W2149093312 @default.
• W2149093312 hasPrimaryLocation W21490933121 @default.
• W2149093312 hasRelatedWork W1797783199 @default.
• W2149093312 hasRelatedWork W1992117911 @default.
• W2149093312 hasRelatedWork W1998570933 @default.
• W2149093312 hasRelatedWork W2035888892 @default.
• W2149093312 hasRelatedWork W2038909026 @default.
• W2149093312 hasRelatedWork W2058357152 @default.

• next